Vaccine Pharmacovigilance & Materiovigilance · Section 14.13

Combination Products & PMSR: When Drug and Device Combine

~5 min read · The Drug Safety Coach — Global PV Career Course

Key points

•A combination product pairs a drug (or biologic) with a device — a prefilled auto-injector, a drug-eluting stent, an inhaler with a dose counter — and safety reporting has to satisfy both drug and device rules at once
•FDA’s Postmarketing Safety Reporting (PMSR) Final Rule, issued December 20, 2016 and codified at 21 CFR Part 4, Subpart B, is the specific regulation governing this dual reporting obligation in the US
•Enforcement phased in by pathway: July 31, 2020 for FAERS/eMDR-based combination product applicants, and January 31, 2021 for those using VAERS — giving industry a multi-year runway to build the necessary dual-reporting processes
•A single adverse event on a combination product can trigger both an ICSR (drug-side, the process this course has covered throughout) and a device malfunction/complaint report (device-side, covered earlier in this module) — the two aren’t interchangeable and both may be required

Listen to this lessonSpeed

Read in:

Full text

This module has covered vaccine PV and standalone device materiovigilance as related but distinct tracks. Combination products sit at the intersection of both, and they’re common enough in current practice — prefilled auto-injectors, drug-eluting stents, metered-dose inhalers with digital dose counters — that understanding how their safety reporting actually works is a genuine gap in most PV training that treats drug and device vigilance as separate subjects.

In the US, this is governed specifically by FDA’s Postmarketing Safety Reporting (PMSR) Final Rule, issued December 20, 2016 and codified at 21 CFR Part 4, Subpart B. The rule requires combination product applicants to report safety information through both drug-side and device-side channels as applicable — not one or the other, but both, since a single adverse event can implicate the drug’s pharmacology, the device’s mechanical function, or both at once.

Enforcement was phased in deliberately, giving industry time to build the necessary processes: July 31, 2020 for combination product applicants using FDA’s Adverse Event Reporting System (FAERS) and Electronic Medical Device Reporting system (eMDR), and January 31, 2021 for those reporting through the Vaccine Adverse Event Reporting System (VAERS). That staggered timeline reflects how genuinely complex building dual-track reporting infrastructure is — it isn’t a simple addition to an existing drug-only or device-only system.

Operationally, this means a case processor working on a combination product needs to ask two questions on every report, not one: does this event need to go through ICSR/E2B(R3) drug-side reporting (the process this course has covered from Module 1 onward), does it need to go through device malfunction/complaint reporting (covered earlier in this module), or — often — both? A device malfunction that also caused patient harm from the drug it delivered is exactly the kind of case where treating it as purely one track or the other would leave a real regulatory gap.

Important

This is a genuinely underrepresented topic in most PV training — device vigilance and drug vigilance are usually taught as separate tracks, but combination products are common in practice (autoinjectors, prefilled syringes, and inhaler-device combinations are everywhere in modern therapeutics) and require someone who understands both sides at once.

Quick check

Test yourself before moving on — no pressure, just click an answer.

1. What does FDA’s Postmarketing Safety Reporting (PMSR) Final Rule, codified at 21 CFR Part 4 Subpart B, require for combination products?

See interview questions for this module →Take the Module Assessment →

← 14.12 Summary and Key References